FDA OKs expanded use of Agilent PD-L1 IHC 22C3 pharmDx in breast cancer

• Agilent Technologies (NYSE:A) has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as an aid in identifying patients with triple-negative breast cancer (TNBC) for treatment with Merck's (NYSE:MRK) Keytruda (pembrolizumab).
• The expanded use of PD-L1 IHC 22C3 pharmDx strengthens the ability of pathologists to identify patients who may be eligible for Keytruda treatment.
• PD-L1 IHC 22C3 pharmDx also helps physicians identify lung cancer, gastric cancer, esophageal squamous cell carcinoma, cervical cancer, urothelial carcinoma, and head and neck squamous cell carcinoma patients.
• https://seekingalpha.com/news/3636418-fda-oks-expanded-use-of-agilents-pd-l1-ihc-22c3-pharmdx-in-breast-cancer